JUL 31, 2018 8:25 PM PDT

Pill Approved For Endometriosis Treatment

WRITTEN BY: Nouran Amin

A first drug, by the name of Elagolix, to treat for endometriosis-related pain, has recently become approved by the US Food and Drug Administration. Endometriosis is caused by uterine tissue moving to another part of the body, usually around the pelvis. The pain, which affects one in ten young women, can cause severe pelvic discomfort during menstruation, sexual intercourse, or all the time. Currently, endometriosis-related pain is managed by common painkillers, contraceptives that work to lessen or block menstruation, or through injectable hormonal treatments. In many cases, women suffering from endometriosis do not benefit from these treatments because they either don’t work, produce unpleasant side-effects such as weight gain or moodiness, or administered for only short periods of time due to the effects of the treatment on bone density.

Fortunately, Elagolix may be taken for longer, but it does come with several side-effects. During a placebo-controlled clinical trial study that examined almost 900 women with moderate to severe endometriosis pain, Elagolix was seen to reduce menstrual pain in over 40 percent of affected women and non-menstrual pelvic pain in over 50 percent when taken orally as a once-daily pill. Elagolix was also seen to reduce average pain ratings during sexual intercourse. The science of Elagolix works by reducing estrogen, the hormone that drives endometriosis. It is believed that because Elagolix slightly reduces the estrogen levels, the drug can be taken for up to two years. On the other hand, injectable hormone treatments, which effectively lower estrogen more powerfully, can only be administered for 6 months because it causes bone loss.

The side-effects that come with taking Elagolix include hot flushes and headaches in about 20 percent of the patient’s examined in the clinical trial with nausea occurring in about 10 percent. “Despite these side-effects, any extra options for treating endometriosis are welcome,” says Elizabeth Farrell, a gynecologist at Jean Hailes, an Australian women’s health organization. Farrell believes that despite the effectiveness of Elagolix, it is unlikely that it will become a first-line treatment for patients. “The oral contraceptive pill or an IUD would probably still be the first thing you tried,” she says.

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 03, 2020
Cannabis Sciences
Cannabis Compound Prevents Colon Cancer in Mice
OCT 03, 2020
Cannabis Compound Prevents Colon Cancer in Mice
Second only to skin cancer, colon cancer is the most common cancer diagnosed in both men and women in the US. Now, resea ...
OCT 20, 2020
Cannabis Sciences
Should Cannabis Doses Be Standardized?
OCT 20, 2020
Should Cannabis Doses Be Standardized?
Should cannabis and its compounds such as tetrahydrocannabinol (THC), the psychoactive compound in cannabis, come in sta ...
OCT 11, 2020
Drug Discovery & Development
Treating Connective Tissue Disorders
OCT 11, 2020
Treating Connective Tissue Disorders
Collaborative research efforts are geared to improving disease that affects connective tissues via innovative drug deliv ...
NOV 17, 2020
Immunology
6 Injections a Year Prevent HIV Infections
NOV 17, 2020
6 Injections a Year Prevent HIV Infections
Last year, around 1.7 million people became infected with HIV, with around half of these being women. Encouraging result ...
NOV 22, 2020
Cannabis Sciences
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
NOV 22, 2020
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescri ...
NOV 18, 2020
Drug Discovery & Development
Hepatitis C Drugs May Be Involved Coronavirus Treatment
NOV 18, 2020
Hepatitis C Drugs May Be Involved Coronavirus Treatment
At the present moment, there are no inhibitors that target protease activity of the novel SARS-CoV-2. The main proteases ...
Loading Comments...